发明名称 Treatment and diagnosis of cancer
摘要 Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen (PSMA) or bind to and are internalized with PSMA. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of PSMA. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cells lines, each of which produces a monoclonal antibody recognizing extracellular domains of PSMA of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.
申请公布号 US8951737(B2) 申请公布日期 2015.02.10
申请号 US200711939422 申请日期 2007.11.13
申请人 Cornell Research Foundation, Inc. 发明人 Bander Neil H.
分类号 G01N33/53;G01N33/574;A61K39/395;A61K47/48;B82Y5/00;C07K16/30;A61K39/00 主分类号 G01N33/53
代理机构 Proskauer Rose LLP 代理人 Zheng Lihua;Consalvi Mary;Proskauer Rose LLP
主权项 1. A method of detecting cancerous tissue in a biological tissue sample comprising: providing an antibody or antigen binding portion thereof which, when contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen, wherein the antibody or antigen binding portion thereof is bound to a label effective to permit detection of vascular endothelial cells proximate to or within the cancerous tissue upon binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue; contacting the biological tissue sample with the antibody or antigen binding portion thereof having a label under conditions effective to permit binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue in the biological tissue sample; detecting a presence of any cancerous tissue in the biological tissue sample by detecting the label; and wherein the antibody is a monoclonal antibody produced by a hybridoma cell line having an ATCC Accession Number selected from the group consisting of HB-12101, HB-12109, HB-12127, and HB-12126.
地址 New York NY US